Revexepride | 219984-49-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Revexepride
• 英文别名: 4-amino-5-chloro-N-[[(3S,4S)-3-hydroxy-1-(3-methoxypropyl)piperidin-4-yl]methyl]-2,2-dimethyl-3H-1-benzofuran-7-carboxamide
• CAS: 219984-49-3
• 化学式: C₂₁H₃₂ClN₃O₄
• 分子量: 425.956
• InChiKey: FOUUNSGQVBGYQM-SUMWQHHRSA-N

物化性质

• 沸点：
  537.5±50.0 °C(Predicted)
• 密度：
  1.216±0.06 g/cm3(Predicted)
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  97
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 储存条件：
  2-8℃

制备方法与用途

生物活性

Revexepride 是一种高度选择性的 5-HT₄ 受体激动剂，也是潜在的 CYP3A4 酶诱导剂，可用于研究胃食管返流疾病。

靶点
5-HT4受体
CYP3A4

体外研究

人类CYP同工酶参与了Revexepride的代谢，在体外主要由CYP3A4（99.9%）代谢，次要贡献来自CYP2D6（0.1%）。 Revexepride 在体外直接抑制人类CYP3A4，其IC₅₀值范围为16-49 μM。

文献信息

• Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
  申请人：——

  公开号：US20020086879A1

  公开（公告）日：2002-07-04

  The present invention of compounds of formula (I) 1 a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, R 1 and R 2 taken together form a bivalent radical of formula wherein in said bivalent radicals one or two hydrogen atoms may be substituted with C 1-6 alkyl; R 3 is hydrogen or halo; R 4 is hydrogen or C 1-6 alkyl; R 5 is hydrogen or C 1-6 alkyl; L is C 3-6 cycloalkyl, C 5-6 cycloalkanone, C 2-6 alkenyl, or L is a radical of formula —Alk—R 6 —, Alk—X—R 7 , —Alk—Y—C(═O)—R 9 , or —Alk—Y—C(═O)— NR 11 R 12 wherein each Alk is C 1-12 alkanediyl; and R 6 is hydrogen, cyano, C 1-6 alkylsulfonylamino, C 3-6 cycloalkyl, C 5-6 cycloalkanone, or a heterocyclic ringsystem; R 7 is hydrogen, C 1-6 alkyl, hydroxyC 1-6 alkyl, C 3-6 cycloalkyl, or a heterocyclic ringsystem; X is O, SO 2 or NR 8 ; said R 8 being hydrogen or C 1-6 alkyl; R 9 is hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 alkyloxy or hydroxy; Y is NR 10 or a direct bond; said R 10 being hydrogen, or C 1-6 alkyl; R 11 and R 12 each independently are hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, or R 11 and R 12 combined with the nitrogen atom may form an optionally substituted pyrrolidinyl, piperidinyl, piperazinyl or 4-morpholinyl ring. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impairment of gastric emptying.

  本发明涉及化合物的一种以及其立体化学异构体形式，N-氧化物形式或药学上可接受的酸加合物盐，其中R1和R2结合在一起形成以下式的二价基团，其中在所述二价基团中一个或两个氢原子可被C1-6烷基取代；R3为氢或卤素；R4为氢或C1-6烷基；R5为氢或C1-6烷基；L为C3-6环烷基，C5-6环戊酮，C2-6烯基，或L为以下式的基团—Alk—R6—，Alk—X—R7，—Alk—Y—C(═O)—R9或—Alk—Y—C(═O)—NR11R12，其中每个Alk为C1-12烷二基；R6为氢，氰基，C1-6烷基磺酰氨基，C3-6环烷基，C5-6环戊酮或杂环环系；R7为氢，C1-6烷基，羟基C1-6烷基，C3-6环烷基或杂环环系；X为O，SO2或NR8；R8为氢或C1-6烷基；R9为氢，C1-6烷基，C3-6环烷基，C1-6烷氧基或羟基；Y为NR10或直接键；R10为氢或C1-6烷基；R11和R12各自独立地为氢，C1-6烷基，C3-6环烷基，或R11和R12与氮原子结合可形成可选择取代的吡咯烷基，哌啶基，哌嗪基或4-吗啉基环。公开了制备所述产品的过程，包括所述产品的制剂以及它们作为药物的用途，特别用于治疗与胃排空障碍有关的病症。
• Bicyclic Benzamides of 3-or 4-Substituted 4-(Aminomethyl)-Piperidine Derivatives
  申请人：Bosmans Jean-Paul René Marie André

  公开号：US20100210657A1

  公开（公告）日：2010-08-19

  The present invention of compounds of formula (I) a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impairment of gastric emptying.

  本发明涉及式(I)化合物，其立体化学异构体形式，N-氧化物形式或药学上可接受的酸加盐形式。公开了制备上述产品的过程，包括含有该产品的制剂以及其作为药物的用途，特别是用于治疗与胃排空障碍相关的疾病。
• Bicyclic Benzamides of 3-Or-4-Substituted 4-(Aminomethyl)-Piperidine Derivatives
  申请人：Bosmans Jean-Paul René Marie André

  公开号：US20120028987A1

  公开（公告）日：2012-02-02

  The present invention of compounds of formula (I) a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impairment of gastric emptying.

  本发明涉及式(I)化合物及其立体化学异构体、N-氧化物形式或药学上可接受的酸加成盐。公开了制备上述产品的过程、包含上述产品的配方以及它们作为药物的用途，特别是用于治疗与胃排空障碍有关的疾病。
• Use of a triple combination comprising a 5ht3 antagonist, a 5ht4agonist and a laxative for promoting intestinal lavage
  申请人：——

  公开号：US20040096423A1

  公开（公告）日：2004-05-20

  The present invention is concerned with the use of a triple combination comprising a 5HT 3 antagonist, a 5HT 4 agonist and a laxative—in particular an osmotic agent—for accelerating intestinal lavage. The present invention is also concerned with the use of said triple combination for the treatment of constipation.

  本发明涉及一种由 5HT 3 拮抗剂、5HT 4 激动剂和一种泻药--特别是一种渗透剂--的三合一组合物，以加速肠道灌洗。本发明还涉及使用上述三合一组合物治疗便秘。
• GASTROKINETIC BICYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATIVES
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP0991410B1

  公开（公告）日：2002-10-30